Back HIV-Related Conditions Liver & Kidney

Liver & Kidney Disease

Johns Hopkins Team Performs Pioneering HIV+ to HIV+ Liver and Kidney Transplants

Doctors at Johns Hopkins announced that they recently performed the first-ever liver transplant and the first kidney transplant in the U.S. from an HIV-positive donor to a recipient living with HIV, made possible by the 2013 HIV Organ Policy Equity (HOPE) Act. Both transplants were successful and the patients are doing "extremely well," infectious disease specialist Christine Durand said at a March 30 press conference.

alt

Read more:

CROI 2015: Tenofovir, Atazanavir & Lopinavir Associated with Raised Risk of Chronic Kidney Disease

Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, researchers reported at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Although the risk of developing chronic kidney disease was low for people with normal kidney function -- with fewer than 1% of patients in the large D:A:D cohort developing it -- the use of any of these drugs was associated with 2 to 3 times higher risk of kidney disease developing over the course of 5 years on the drug.

alt

Read more:

HIVMA Issues Guidelines for Managing Chronic Kidney Disease in People with HIV

The HIV Medical Association (HIVMA) of the Infectious Diseases Society of America (IDSA) has released updated recommendations for HIV positive people with chronic kidney disease. The guidelines, published in the September 17 issue of Clinical Infectious Diseases, state that antiretroviral therapy (ART) is beneficial for such patients, but they should avoid tenofovir (Viread, also in the Truvada, Atripla, Complera, and Stribild coformulations), which can cause kidney impairment.

alt

Read more:

HIV Rebound Linked to Liver Fibrosis Progression in HIV/HCV Coinfected

HIV-positive people with hepatitis C virus (HCV) experienced progression to liver fibrosis if their HIV viral load rebounded above 1000 copies/mL or remained detectable on 2 consecutive tests, researchers reported in the January edition of HIV Medicine. Smaller transient HIV "blips," however, were not associated with worsening fibrosis. Optimized antiretroviral therapy, the study authors suggested, may protect the liver.

alt

Read more:

CROI 2014: Tesamorelin Growth-Hormone Releaser Reduces Liver Fat in People with HIV

Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), which the FDA has approved to reduce excess visceral abdominal fat in people living with HIV, also reduced associated liver fat in an HIV positive cohort chosen for abdominal adiposity, according to the results from a randomized, placebo-controlled trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

Read more: